Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502–1517.
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous IFN beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903–914.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg IFN beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889–897.
   PubMed Web of Science ®Google Scholar
• Kalincik T, Jokubaitis V, Izquierdo G, et al. Comparative effectiveness of glatiramer acetate and IFN beta formulations in relapsing-remitting multiple sclerosis. Mult Scler. 2015 Aug;21(9):1159–1171.
   PubMed Web of Science ®Google Scholar
• Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2016 Jan;23(Suppl 1):18–27.
   PubMed Web of Science ®Google Scholar
• Fernandez O, Fernandez V, Mayorga C, et al. HLA class II and response to IFN-beta in multiple sclerosis. Acta Neurol Scand. 2005;112:391–394.
   PubMed Web of Science ®Google Scholar
• Dörr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015 Jun;17(6):354. 8.
   PubMed Web of Science ®Google Scholar
• Kalincik T, Horakova D, Spelman T, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol. 2015 Mar;77(3):425–435.
   PubMed Web of Science ®Google Scholar
• Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis switching from IFN to fingolimod or glatiramer acetate: a US claims database study. Plos One. 2014;9(2):e88472.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Leone C, Zanghì A, et al. Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. J Neurol. 2016 Sep;263(9):1802–1809.
   PubMed Web of Science ®Google Scholar
• What is MSBase. MSBase registry website. Available from:https://www.msbase.org.
   Google Scholar
• Poser C, Paty D, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–231.
   PubMed Web of Science ®Google Scholar
• Rotstein DL, Healy BC, Malik MT, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015 Feb;72(2):152–158.
   PubMed Web of Science ®Google Scholar
• European study group on IFN beta‐1b in secondary progressive MS. Placebo‐controlled multicenter randomised trial of IFN beta‐1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;3521491:1497.
   Google Scholar
• Rovira A, Auger C, Alonso J. Magnetic resonance monitoring of lesion evolution in multiple sclerosis. Ther Adv Neurol Disord. 2013 Sep;6(5):298–310.
   PubMed Web of Science ®Google Scholar
• Lewis JH. The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2173–2189. e8. Epub 2015 Jun 23.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Sacca F, Cordioli C, et al. Prosperini Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment naıve patients with multiple sclerosis. J Neurol. 2017;264:284–294.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular IFN for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–415.
   PubMed Web of Science ®Google Scholar
• Barbin L, Rousseau C, Jousset N, et al. Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study. Neurology. 2016 Feb 23;86(8):771–778.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Kern R, Cornelissen C, et al. The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurol. 2015 Jun;18(15):93.
   Web of Science ®Google Scholar
• Braune S, Lang M, Bergmann A, et al. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. J Neurol. 2016 Feb;263(2):327–333. 21.
   PubMed Web of Science ®Google Scholar
• He A, Spelman T, Jokubaitis V, et al. Comparison of switch to fingolimod or IFN beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol. 2015 Apr;72(4):405–413.
   PubMed Web of Science ®Google Scholar
• Roskell NS, Zimovetz EA, Rycroft CE, et al. Annualized relapse rate of first line treatments for multiple sclerosis: a metanalysis, including indirect comparisons versus fingolimod. Curr Med Res Opin. 2012;28:767–780.
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Doxani C, Mprotsis RT, et al. Network analysis of randomized controlled trials in multiple sclerosis. Clin Ther. 2012;34:857–869.
   PubMed Web of Science ®Google Scholar
• Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013 6;Jun(6):CD008933.
   Google Scholar
• Ziemssen T, Banjar OA, Carrá A, et al. A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J Neurol. 2014 Nov;261(11):2101–2111.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Leone C, Caserta C, et al. Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Rev Neurother. 2015;15(7):803–824.
   PubMed Web of Science ®Google Scholar
• Reynolds MW, Stephen R, Seaman C, et al. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ. 2010;13:90–98.
   PubMedGoogle Scholar
• Rich SR, Coleman IC, Cook R, et al. Stepped-care approach to treating MS: a managed care treatment algorithm. J Manag Care Pharm. 2004;10:S26–32.
   PubMedGoogle Scholar
• Chin PS, U PA, Zhang Y, et al. Early effect of fingolimod on clinical and MRI related outcomes in relapsing multiple sclerosis. Multiple Sclerosis. 2012;18(S4):55–277.
   Google Scholar